Dysphoria News and Research

RSS

Unique challenges in providing psychotherapy to people with ASD and gender dysphoria

The challenges in providing psychotherapy to individuals with autism spectrum disorders (ASD) who also are struggling with their gender identity are explored in two case studies of high-functioning persons with diagnoses of ASD and gender dysphoria (GD).

3 Dec 2014

Medicare to cover sex-change surgery

The ruling, handed down Friday by a Department of Health and Human Services appeals board, reverses a Medicare policy in place since 1981. It covers surgery, but not other treatments like hormones.

3 Jun 2014

First Edition: June 2, 2014

Today's headlines include reports about state health law implementation activities as well as the next steps regarding the difficulties at the VA health system.

2 Jun 2014

Novel scaffold protein regulates mu opioid receptor induced signaling activation

Researchers found initial confirmation that a novel scaffold protein previously unassociated with the mu opioid receptor (MOR) regulates MOR-induced signaling activation.

4 Mar 2014

State highlights: N.C. Medicaid reform plan unveiled; cutting back Medicaid estate recoveries

A selection of health policy stories from Arizona, Colorado, Connecticut, D.C., Florida, New York, and North Carolina.

3 Mar 2014

First Edition: February 28, 2014

Today's headlines include reports about the latest developments for those states that are running their own health insurance exchanges and facing difficulties.

28 Feb 2014

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.

13 Dec 2013

Hormone treatment to halt puberty in transgender adolescents is safe and effective

Hormone treatment to halt puberty in adolescents with gender identity disorder does not cause lasting harm to their bones, a new study finds. The results were presented today at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

TSRI scientists find emotion-related brain region plays major role in sustaining cocaine addiction

Scientists at The Scripps Research Institute (TSRI) have found evidence that an emotion-related brain region called the central amygdala—whose activity promotes feelings of malaise and unhappiness—plays a major role in sustaining cocaine addiction.

13 Jun 2013

LGBT Health journal presents in-depth perspective on gender diagnoses

LGBT Health, a new peer-reviewed journal from Mary Ann Liebert, Inc., publishers, launching in fall 2013, presents a timely and in-depth perspective on several key controversies surrounding gender diagnoses.

18 May 2013

Feds boost rather than cut payments to Medicare Advantage plans

The insurance industry won a major lobbying victory Monday after the Obama administration backtracked on an earlier plan to cut Medicare Advantage payments to insurers by 2.2 percent in 2014 and instead decided to give them a 3.3 percent increase.

3 Apr 2013

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.

11 Dec 2012

Gabapentin drug helps people to quit cannabis

Scientists at The Scripps Research Institute have found clinical evidence that the drug gabapentin, currently on the market to treat neuropathic pain and epilepsy, helps people to quit smoking marijuana.

24 Apr 2012

Coffee reduces risk of depression in older women: Study

A new study shows that risk of depression decreases as coffee consumption increases. The findings however apply only to post-menopausal women who smoke.

27 Sep 2011

New research uncovers role of p38alpha in mood disorders, addiction

Stressful experiences increase addictive drug consumption and can precipitate bouts of anxiety or depression in vulnerable people. Although the mechanisms linking stress and human behaviors are not well understood, animal models of some aspects of these behaviors have been developed and have been used to define some of the molecular events that may be responsible for stress vulnerability in people.

11 Aug 2011

FDA approves Gilead's Complera for treatment of HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Complera, a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.

11 Aug 2011

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor EDURANT tablets versus efavirenz (EFV) in antiretroviral treatment-naive, HIV-1-infected adults.

20 Jul 2011

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

Cypress Pharmaceutical announced today that the Food and Drug Administration (FDA) approved a new drug application (NDA) for ZUTRIPRO Oral Solution (CIII) and REZIRA Oral Solution.

14 Jun 2011

Post-sex blues in nearly 10% of women: Study

A new study suggests that many women do feel depressed after sex. The study involved more than 200 young Australian women who were questioned about their sex lives. At least one in three young women said they experienced post-coital blues at some point in their lives. Ten per cent said they frequently or almost always felt sad after making love. The study was published in the quarterly International Journal of Sexual Health.

31 Mar 2011

QUT study finds 32.9% of young women experience post-sex blues

Post-sex blues is not a sexual behaviour commonly discussed, but a Queensland University of Technology study of more than 200 young women has found one in three had experienced the phenomenon at some point.